Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Accumulated Expenses (2019 - 2026)

ADC Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $57.7 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $57.7 million for Q1 2026, up 36.72% from a year ago — trailing twelve months through Mar 2026 was $57.7 million (up 36.72% YoY), and the annual figure for FY2025 was $58.0 million, down 7.13%.
  • Accumulated Expenses reached $57.7 million in Q1 2026 per ADCT's latest filing, down from $58.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $62.4 million in Q4 2024 and bottomed at $30.7 million in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $53.3 million (2024), compared with a mean of $51.0 million.
  • The largest annual shift saw Accumulated Expenses surged 69.64% in 2023 before it fell 13.29% in 2025.
  • Over 5 years, Accumulated Expenses stood at $30.7 million in 2022, then soared by 69.64% to $52.1 million in 2023, then grew by 19.84% to $62.4 million in 2024, then dropped by 7.13% to $58.0 million in 2025, then decreased by 0.5% to $57.7 million in 2026.
  • Business Quant data shows Accumulated Expenses for ADCT at $57.7 million in Q1 2026, $58.0 million in Q4 2025, and $53.9 million in Q3 2025.